Business Context and Reporting Period
Company: Canopy Growth Corp (CGC)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and six months ended September 30, 2024 (Fiscal Q2 2025)
Business Overview: Canopy Growth is a global cannabis company producing and selling cannabis products for adult-use and medical purposes in Canada, Europe, and Australia. The company also operates the Storz & Bickel vaporizer business. A significant portion of the company's U.S. strategy is now held through Canopy USA, LLC, which was deconsolidated from Canopy Growth's financial statements effective April 30, 2024, following structural amendments to comply with Nasdaq listing requirements.
Key Financial Metrics
| Metric (CAD in thousands) | Three Months Ended Sept 30, 2024 | Six Months Ended Sept 30, 2024 |
|---|---|---|
| Net Revenue | $62,991 | $129,203 |
| Gross Margin | $21,838 (35%) | $44,869 (35%) |
| Operating Loss | $(45,943) | $(75,051) |
| Net Loss (Continuing Ops) | $(131,550) | $(260,741) |
| Net Loss (Total) | $(128,293) | $(255,431) |
| Cash and Cash Equivalents | $228,416 | $228,416 |
| Total Debt (Principal) | $574,100 | $574,100 |
| Free Cash Flow | $(56,441) | $(112,141) |
Note: All currency amounts are in Canadian dollars unless otherwise noted. Net loss includes discontinued operations (BioSteel) which generated a net income of $3.3 million for the quarter and $5.3 million for the six months.
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased 9% year-over-year (YoY) for the quarter and 11% YoY for the six months. This was driven by a 24% decline in Canadian adult-use cannabis sales due to supply constraints and price competition, partially offset by growth in medical cannabis (+16% QoQ) and Storz & Bickel (+32% QoQ).
- Margin Expansion: Gross margin percentage improved to 35% for both the quarter and six months, up from 34% and 25% respectively in the prior year periods. This improvement is attributed to cost savings initiatives, reduced inventory write-downs, and a shift to higher-margin medical and international sales.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses decreased significantly (28% for the quarter) due to the divestiture of "This Works" and ongoing restructuring. However, total operating expenses increased due to a $20.8 million loss on asset impairment and restructuring, compared to a gain of $29.9 million in the prior year quarter.
- Other Income/Expense: Non-cash fair value adjustments on financial assets and equity method investments resulted in a significant expense of $85.3 million for the quarter, primarily related to the Canopy USA equity method investment and Acreage debt instruments.
- Deconsolidation: Canopy USA was deconsolidated as of April 30, 2024. The company now accounts for its interest in Canopy USA as an equity method investment valued at $136.4 million.
Guidance, Outlook, and Risks
- Going Concern: Management states that substantial doubt regarding the company's ability to continue as a going concern has been alleviated following balance sheet deleveraging, equity financings, and debt amendments.
- Liquidity Strategy: The company established an At-The-Market (ATM) equity program in June 2024, raising $138.5 million in gross proceeds during the six-month period. It also extended the maturity of its Credit Facility to December 2026 and made a mandatory prepayment of US$100 million in October 2024.
- U.S. Strategy (Canopy USA): Canopy USA has exercised options to acquire Wana and Jetty and is in the process of acquiring Acreage. The success of this strategy depends on the satisfaction of closing conditions and the financial stability of Acreage, which has expressed doubt about its own ability to continue as a going concern.
- Legal Proceedings: The company is subject to an ongoing SEC investigation regarding the BioSteel revenue recognition review. Several shareholder class actions related to BioSteel disclosures were dismissed in July 2024, with appeals subsequently dismissed in October 2024.
- Restructuring: The company continues to execute cost-saving plans, including facility closures and workforce reductions, to improve operational efficiency.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the amended Credit Facility covenants, specifically the minimum liquidity requirements and the impact of the mandatory US$100 million prepayment made in October 2024.
- Acreage Acquisition Status: Monitor the progress of the Acreage acquisition by Canopy USA, given Acreage's own going concern warnings and the complexity of the Floating Share Arrangement.
- Equity Dilution: Track the utilization of the ATM program and the potential dilution from the May 2024 Convertible Debenture and outstanding warrants.
- SEC Investigation: Review updates on the SEC investigation regarding BioSteel to assess potential fines, penalties, or restatement risks.
- Canadian Market Dynamics: Assess the sustainability of the revenue decline in the Canadian adult-use market and the effectiveness of the company's pricing and supply chain strategies.